-
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across
Lifestyle Content
Technology
-
Terrik Saint Claire Announces January Publication of The International Practitioner’s Sports Law Handbook
-
International Medical Aid Brings Global Health Education to the 2026 UC Davis Pre-Health Conference
-
Ramsey Financial Group Names Meagan Murphy Crawford Partner
-
The $310,000 Warning Sign Texas Schools Keep Missing in the Absenteeism Fight
-
ALTO Salida Unveils Limited-Time Buyer Incentives, Including One Year of HOA Dues and Monarch Ski Area 4-Pack
Entertainment
-
Mango AI Brings AI Video Face Swap to Short Clips
-
30+ Years Fighting for Massachusetts’s Injured Workers: Attorney John J. Sheehan’s Bilingual Practice
-
Mike Bolger Receives Two Diamond Awards in Waterloo and Cambridge Readers’ Choice 2026
-
Torham Exterior Solutions Wins Diamond for Best Roofing Company in Hamilton 2026
-
Reitzel Insulation Earns Five Diamond Awards in Cambridge and Waterloo
Health
-
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
-
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
-
Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details
-
Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
-
Rosen Law Firm Encourages NVE Corporation Investors to Inquire About Securities Class Action Investigation – NVEC
